[PRESS RELEASE] – CHICAGO, May 27, 2026 – Cresco Labs Inc., the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, announced that it registered certain state-licensed medical cannabis facilities with the U.S. Drug Enforcement Administration (DEA) following the federal rescheduling of medical cannabis to Schedule III under the Controlled Substances Act.
The registrations relate to dispensary, cultivation and processing operations serving medical cannabis patients within the company’s footprint.
“Registering our medical cannabis operations with the DEA marks a significant milestone for Cresco Labs and for the continued evolution of the cannabis industry,” Cresco Labs CEO Charlie Bachtell said. “For the first time, the work we do is federally recognized – advancing normalization, reducing uncertainty and reinforcing safe, responsible access to medicine for patients across the country.”
The expedited 60-day DEA registration pathway was established following the federal government’s rescheduling of medical marijuana to Schedule III, which created a mechanism for eligible state-licensed medical cannabis operators to register certain activities with the DEA.
This news release constitutes a “designated news release” for the purposes of the company’s prospectus supplement dated Jan. 29, 2026, to its short form base shelf prospectus dated Oct. 3, 2025.
